Drug
Brigatinib clinical trials
Also written AP26113 and Alunbrig.
- studies test it
- 26
- open now
- 3
- in phase 3
- 2
- first study started
- 2011
Keep track of what changes. Save the brigatinib studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
26 studies that test it; most in 2020 (9)
| Year | Studies |
|---|---|
| 2011 | 1 |
| 2014 | 1 |
| 2016 | 1 |
| 2017 | 1 |
| 2018 | 3 |
| 2019 | 5 |
| 2020 | 9 |
| 2022 | 2 |
| 2023 | 1 |
| 2024 | 1 |
| 2025 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 8
- Phase 2
- 19
- Phase 3
- 2
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 10 · Other 16
Takeda (5) · Ariad Pharmaceuticals (4) · City of Hope Medical Center (1) · Fundación GECP (1) · M.D. Anderson Cancer Center (1) · Fondazione per la Medicina Personalizzata (1) · JI-YOUN HAN (1) · Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest (1)
Often tested with
Tested in the same studies.
Bevacizumab (2) · Cobimetinib (2) · Alectinib (2) · Ponatinib (2) · Neratinib (2) · Ceritinib (2) · Erlotinib (1) · Trastuzumab (1)
Studies
Open first, then newest update. How each study uses brigatinib is read from its arms, and is right about nine times in ten.
Testing it · 26
- Innovative Trial for Understanding the Impact of Targeted Therapies in NF2-Related Schwannomatosis (INTUITT-NF2)RecruitingPhase 2Scott R. Plotkin, MD, PhDNCT04374305Written as Brigatinib
- Using Tumor Models to Determine TreatmentsRecruitingPhase 2University Health Network, TorontoNCT06813079Written as Brigatinib
- Brigatinib in Pediatric and Young Adult Patients With ALK+ ALCL, IMT or Other Solid TumorsRecruitingPhase 1/2Princess Maxima Center for Pediatric OncologyNCT04925609Written as Brigatinib
- Brigatinib and Bevacizumab for the Treatment of ALK-Rearranged Locally Advanced, Metastatic, or Recurrent NSCLCActive, not recruitingPhase 1City of Hope Medical CenterNCT04227028Written as Brigatinib
- Advancing Brigatinib Properties in ALK+ NSCLC Patients by Deep PhenotypingCompletedPhase 2Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus NordwestNCT04318938Written as Brigatinib
- Targeted Treatment for ALK Positive Patients Who Have Previously Been Treated for Non-squamous Non-small Cell Lung CancerTerminatedPhase 2National Cancer Institute (NCI)NCT03737994Written as Brigatinib
- Clinical Utility of Liquid Biopsy in Brigatinib ALK+ PatientsActive, not recruitingPhase 2Fundación GECPNCT04223596Written as Brigatinib
- Local Consolidative Therapy and Brigatinib in Treating Patients With Stage IV or Recurrent Non-small Cell Lung CancerActive, not recruitingPhase 1M.D. Anderson Cancer CenterNCT03707938Written as Brigatinib
- A Study of Brigatinib Compared to Alectinib in Adults With Non-Small-Cell Lung CancerCompletedPhase 3TakedaNCT03596866Written as Brigatinib
- A Study of Brigatinib in Participants With Anaplastic Lymphoma Kinase-Positive (ALK+), Advanced Non-Small-Cell Lung Cancer (NSCLC) Progressed on Alectinib or CeritinibCompletedPhase 2Ariad PharmaceuticalsNCT03535740Written as Brigatinib
- A Study to Compare the Relative Bioavailability of Brigatinib When Swallowed as a Solution Versus When Swallowed as a Tablet in Healthy AdultsCompletedPhase 1TakedaNCT06132867Written as Brigatinib
- Brigatinib Post Definitive Chemo-radiotherapy in Patients with ALK-fusion Non-small Cell Lung CancerWithdrawnPhase 2ETOP IBCSG Partners FoundationNCT05718297Written as Brigatinib
- Phase 2 Study of Brigatinib in Japanese Participants With Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small Cell Lung Cancer (NSCLC)CompletedPhase 2TakedaNCT03410108Written as Brigatinib
- The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and ImmunotherapyActive, not recruitingPhase 2Fondazione per la Medicina PersonalizzataNCT04591431Written as Brigatinib
- Brigatinib in ALK-positive NSCLC Identified Via Blood-based AssaysActive, not recruitingPhase 2JI-YOUN HANNCT04074993Written as Brigatinib
- A Phase 1 Drug-Drug Interaction Study Between Brigatinib and the CYP3A Substrate, Midazolam, in Participants With ALK-Positive or ROS1-Positive Solid TumorsCompletedPhase 1TakedaNCT03420742Written as Brigatinib
- Trial of Brigatinib After Treatment With Next-Generation ALK InhibitorsTerminatedPhase 2Criterium, Inc.NCT02706626Written as brigatinib
- Brigatinib Before Brain Irradiation Trial (B3i Trial)TerminatedPhase 2University of Colorado, DenverNCT04634110Written as Brigatinib
- Brigatinib and Binimetinib in Treating Patients With Stage IIIB-IV ALK or ROS1-Rearranged Non-small Cell Lung CancerTerminatedPhase 1University of California, San FranciscoNCT04005144Written as Brigatinib
- A Window of Opportunity Study for Investigating Drug Tolerant Persister (DTP) to Preoperative Brigatinib in Resectable Non-small Cell Lung Cancer (NSCLC) Harboring ALK Fusions.Status unknownPhase 2Yonsei UniversityNCT05361564Written as Brigatinib
See all 26 studies that test brigatinib →
Given in every arm · 2 — brigatinib is usual care beside what is tested
- Study of Safety and Efficacy of Brigatinib Plus Chemotherapy or Brigatinib Only in Advanced ALK-Positive Lung Cancer (MASTERPROTOCOL ALK)Active, not recruitingPhase 2Intergroupe Francophone de Cancerologie ThoraciqueNCT05200481Written as Brigatinib 180 MG
- Brigatinib Plus Chemotherapy or Local Consolidation Therapy in ALK Positive Advanced Non-small Cell Lung Cancer (BrightStar-2)WithdrawnPhase 2M.D. Anderson Cancer CenterNCT06522360Written as Brigatinib
Codes
What other systems call brigatinib · ClinicalTrials.gg INT000241
- MeSH (NLM) C000598580brigatinibConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) HYW8DB273JBRIGATINIBConfirmed FDA, NLM, Wikidata
- RxNorm 1921217Confirmed FDA, Wikidata
- Wikidata Q27456393brigatinibConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C98831BrigatinibConfirmed FDA, Wikidata
- DrugBank DB12267One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000598580 | brigatinib | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | HYW8DB273J | BRIGATINIB | Confirmed FDA, NLM, Wikidata |
| RxNorm | 1921217 | — | Confirmed FDA, Wikidata |
| Wikidata | Q27456393 | brigatinib | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C98831 | Brigatinib | Confirmed FDA, Wikidata |
| DrugBank | DB12267 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.